Loading
Life sciences · Journal article
Journal of Chemistry of Goods and Traditional Medicine · September 11, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is one of the most prevalent chronic metabolic disorders worldwide and is strongly associated with an increased risk of type 2 diabetes mellitus, cardiovascular disease, arterial hypertension, and metabolic syndrome. In recent years, glucagon-like peptide-1 receptor agonists, orlistat, and centrally acting anti-obesity medications have been widely used in obesity treatment. Although these agents demonstrate considerable clinical efficacy, their long-term use may be associated with adverse reactions. At the same time, phytotherapeutic products derived from medicinal plants have attracted growing scientific interest because of their antioxidant, anti-inflammatory, and metabolism-regulating properties. This article provides a comparative analysis of the efficacy, safety, and mechanisms of action of chemical anti-obesity drugs and phytotherapeutic agents based on current scientific evidence.